Abvc Biopharma (ABVC) Shares Outstanding (2010 - 2026)
Abvc Biopharma's (ABVC) quarterly Shares Outstanding (Entity) came in at $25.8 million in Q1 2026, up 67.56% YoY from $15.4 million in Q1 2025, and up 28.14% on a QoQ basis from $20.1 million in Q4 2025.
Abvc Biopharma (ABVC) Shares Outstanding (2010 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has 17 years of Shares Outstanding (Entity) data on file, last reported at $25.8 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 67.56% year-over-year to $25.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.8 million (up 67.56% YoY) and the FY2025 annual result came in at $20.1 million, up 45.0% from the prior year.
- Shares Outstanding (Entity) climbed to $25.8 million in Q1 2026, from $20.1 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $25.8 million in Q1 2026 to a low of $3.0 million in Q1 2022.
- A 5-year average of $10.8 million and a median of $10.7 million in 2024 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) grew 2.39% — and 2024, when it jumped 264.32%.
- Tracing ABVC's Shares Outstanding (Entity) over 5 years: stood at $3.3 million in 2022, then jumped by 31.95% to $4.3 million in 2023, then soared by 219.87% to $13.9 million in 2024, then soared by 45.0% to $20.1 million in 2025, then increased by 28.14% to $25.8 million in 2026.
- The last three Shares Outstanding (Entity) figures came in at $25.8 million (Q1 2026), $20.1 million (Q4 2025), and $24.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Abvc Biopharma | 23.19 Mn | 23.19 Mn | - | 26.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.45 Mn |
| Mar 31, 2026 | 25.45 Mn |
| Dec 31, 2025 | 20.11 Mn |
| Sep 30, 2025 | 23.26 Mn |
| Jun 30, 2025 | 17.39 Mn |
| Mar 31, 2025 | 14.97 Mn |
| Dec 31, 2024 | 11.67 Mn |
| Sep 30, 2024 | 12.41 Mn |
| Jun 30, 2024 | 11.32 Mn |
| Mar 31, 2024 | 9.74 Mn |
| Dec 31, 2023 | 4.34 Mn |
| Sep 30, 2023 | 4.06 Mn |
| Jun 30, 2023 | 3.31 Mn |
| Mar 31, 2023 | 3.31 Mn |
| Dec 31, 2022 | 3.17 Mn |
| Sep 30, 2022 | 3.26 Mn |
| Jun 30, 2022 | 3.13 Mn |
| Mar 31, 2022 | 2.97 Mn |
| Dec 31, 2021 | 2.51 Mn |
| Sep 30, 2021 | 2.69 Mn |